Peter Fedichev’s Physics-Based Approach to Aging: A New Longevity Framework

Peter Fedichev describes aging as a three-variable system of stress (from physical, psychological, or molecular stressors), noise (small random biological fluctuations), and damage (cumulative wear-and-tear).

Peter Fedichev has proposed a physics-based framework for aging, encompassing stress, noise (small random biological fluctuations), and damage (cumulative wear-and-tear).

Aging &amp; Longevity

Approved Human Study Sets Up Pivotal Test for Aging Theory from Harvard’s David Sinclair

In a major proving ground test for the longevity field, the FDA has given its approval for a human trial for a gene therapy attempting a near-total rejuvenating reset of cells.

(David Sinclair, Michael Ringel, Sharon Rosenzweig-Lipson, and Jerry McLaughlin of Life Biosciences | Longevity.technology)

The FDA has greenlighted Life Biosciences’ first human trial testing whether their gene therapy can confer a near-total rejuvenating reset of cells.

Clinical Trials

The Rise of China’s Longevity Movement: A Quest to Defy Aging

China’s national project to crush aging encompasses longevity labs, “immortality islands,” and grapeseed pills, as well as exorbitant claims based on sometimes questionable science.

(Attendees at a conference in Shanghai try out a cryogenic chamber in which temperatures plummeted to approximately -200 degrees Fahrenheit, meant to slow aging | New York Times)

A surge in the Chinese public’s interest in longevity science has led to substantial investments from the state and private companies in aging research.

The Latest Insight on Anti-Aging Therapeutics Targeting Cardiovascular Disease

According to French scientists, no organ system appears as vulnerable to aging as the cardiovascular system, and anti-aging therapeutics may help mitigate the effects of cardiovascular disease.

(The principal investigator behind the review, aging researcher Guido Kroemer | Olympiad in Cardiovascular Medicine)

Anti-aging therapeutics may prevent and slow age-related cardiovascular dysfunction.

Cardiovascular

<p>Model: C3B6F1 hybrid mice<br />
Dosage: 42 mg/kg of rapamycin and 1.44 mg/kg of trametinib in food starting at 6 months of age</p>


Latest Research: Two FDA-Approved Drugs Additively Extend Lifespan

Researchers at the Max Planck Institute have unveiled that combining trametinib with rapamycin, drugs used in cancer treatment, extends average lifespan by 29% in female mice and 27% in male mice, respectively.

(The study’s lead author, Linda Partridge | The Biologist)

Combining two cancer treatment drugs, trametinib and rapamycin, extends lifespan by 29% and 27% in middle-aged female and male mice, respectively.

Search Result: Aging Therapeutics

Peter Fedichev’s Physics-Based Approach to Aging: A New Longevity Framework

FDA Greenlights Life Biosciences’ Human Study, Setting Up Pivotal Test for Aging Theory from Harvard’s David Sinclair

The Rise of China’s Longevity Movement: A Quest to Defy Aging

The Latest Insight on Anti-Aging Therapeutics Targeting Cardiovascular Disease

Latest Research: Two FDA-Approved Drugs Additively Extend Lifespan